T-cell therapy in the treatment of post-transplant lymphoproliferative disease

Catherine M. Bollard, Cliona M. Rooney, Helen E. Heslop

Research output: Contribution to journalReview articlepeer-review

199 Scopus citations


Post-transplant lymphoproliferative diseases (PTLD) associated with Epstein-Barr virus (EBV) infection often develop after organ and haematopoietic stem-cell transplantation. These lymphoproliferative diseases are tumours that usually express all latent EBV viral proteins, and are therefore amenable to T-cell-based immune therapies, such as donor lymphocyte infusions and the adoptive transfer of EBV-specific cytotoxic T lymphocytes. In this Review, we describe current approaches of T-cell-based therapies to treat PTLD, and describe strategies that improve the feasibility of such treatment.

Original languageEnglish (US)
Pages (from-to)510-519
Number of pages10
JournalNature Reviews Clinical Oncology
Issue number9
StatePublished - Sep 2012

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'T-cell therapy in the treatment of post-transplant lymphoproliferative disease'. Together they form a unique fingerprint.

Cite this